The BA.3.2 variant of COVID-19 was first identified in a respiratory sample collected in South Africa in November 2024. It is a heavily mutated subvariant of Omicron and has since spread to 25 states in the U.S. Since its detection in the U.S. on June 27, 2025, this variant has been confirmed in 132 wastewater samples across multiple regions, indicating significant community spread. Cases have been identified in both patients and travelers, raising alarms among health officials. As of February 2026, the Centers for Disease Control and Prevention reported that detections of BA.3.2 began increasing in September 2025, with the virus frequently identified in wastewater before clinical tests confirmed its presence. This trend highlights the variant's growing prevalence and the potential challenges it poses to public health efforts. Reported symptoms among individuals infected with BA.3.2 are largely consistent with those seen in other Omicron-related strains, including cough, fever, fatigue, and sore throat. However, some cases have noted less frequent loss of smell or taste compared to earlier variants. Health experts emphasize that the severity of symptoms can vary based on factors like age and prior immunity from vaccinations or previous infections, and asymptomatic cases have also been documented. What makes BA.3.2 particularly concerning is the high number of mutations it possesses, with approximately 70 to 75 changes in its spike protein compared to the JN.1 lineage viruses targeted by existing vaccines. These mutations have the potential to compromise the effectiveness of vaccine-acquired immunity. Despite laboratory studies suggesting reduced antibody neutralization against BA.3.2, the CDC and the World Health Organization have not reported evidence that this variant leads to more severe illness than other circulating strains. Health officials continue to advocate for staying updated with vaccinations as the most effective strategy to mitigate severe disease risks associated with emerging variants.